Fred Kerley Faces Two-Year Ban Amid Controversy Over Drug Testing

American sprinter Fred Kerley, the 2022 World Championships 100m gold medallist, has been handed a two-year ban for missing drug tests. Despite this suspension, he plans to compete in the Enhanced Games in 2025, a league that allows performance-enhancing drugs. Kerley has expressed frustration over the AIU's disciplinary process, questioning the fairness of being asked to cover legal costs while facing allegations. He has raised concerns about the integrity of the AIU, citing internal misconduct and the financial burden placed on athletes. With a decorated career, including Olympic medals and world titles, Kerley's situation highlights ongoing issues in the world of athletics.

By Narendra Chaudhary Mar 7, 2026, 13:11 IST

Fred Kerley's Suspension Details

Fred Kerley, the American sprinter who clinched gold in the 100m at the 2022 World Championships, has received a two-year suspension from the Athletics Integrity Unit (AIU) due to missed drug tests. Despite this ban, Kerley is set to compete in the Enhanced Games in September 2025, making him the first prominent track athlete to join this new league that allows performance-enhancing substances.

The AIU, responsible for monitoring athletes' compliance with anti-doping regulations, announced Kerley's suspension via social media. The ban is effective from August 12, 2025, until August 11, 2027. The AIU stated, "A Disciplinary Tribunal has banned Fred Kerley (USA) for 2 years, from 12 August 2025, for Whereabouts Failures. DQ results since 6 December 2024." They described Kerley as 'negligent and, to a certain extent, reckless' for not following the anti-doping protocols, with missed tests occurring between May and December 2024.

Kerley's Response to the Ban

In response to the suspension, Kerley expressed his frustration with the disciplinary process through various social media posts. He criticized the AIU for not only pursuing disciplinary action against him but also demanding a $3,000 contribution towards the costs associated with the case linked to World Athletics.

Kerley questioned the fairness of the situation, arguing that the same organization that initiated the allegations against him is also expecting him to cover their legal expenses. He emphasized that athletes already contribute significantly to the sport through their performances and public personas, and it seems unjust to require them to fund the disciplinary system that targets them.

Concerns Over the System

Kerley raised concerns about the AIU's practices, suggesting that the prevalence of whereabouts violations among athletes is crucial for maintaining the enforcement structure. He hinted that the system might struggle to operate without a steady influx of such cases.

He also pointed out an internal audit revealing that over $1.5 million had been misappropriated by AIU staff, questioning why athletes should bear the financial burden when such issues exist within the organization. In another tweet, he stated, "I’m tired of holding everything in. You can’t control me, and the truth is louder than silence." Under the World Anti-Doping Code, athletes are considered in violation after three missed tests or filing failures within a year. The AIU noted that a fourth alleged failure on December 7 was not counted by the tribunal, as the initial three violations were sufficient for the ruling.

Kerley's Athletic Achievements

Kerley has had a remarkable career, highlighted by his gold medal in the 100m at the 2022 World Athletics Championships and two world titles in the men’s 4x100m relay in 2019 and 2023. He has also earned Olympic medals in the 100m, securing silver at the Tokyo 2020 Olympics and bronze at the Paris 2024 Olympics. Although he did not contest the missed test recorded on June 13, he attributed a missed test on May 11 to technical issues with the United States Anti-Doping Agency (USADA) app and blamed the Doping Control Officer for the December missed tests. The ruling can be appealed to the Court of Arbitration for Sport (CAS).